---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-237632"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:42:25.253972+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Taysha discontinues TSHA-120 in GAN; extends cash runway to Q4 2025 for TSHA-102

## Summary
- Taysha discontinues TSHA-120 for giant axonal neuropathy after FDA Type C feedback cited study design challenges for BLA.
- Astellas Gene Therapies declined its option to license TSHA-120.
- Cash runway extended into Q4 2025 by prioritizing TSHA-102 for Rett syndrome.
- Ongoing REVEAL Phase 1/2 trial for TSHA-102 in adults; pediatric trial planned.
- Taysha to pursue external strategic options for TSHA-120 to enable further development.

## SEC filing metadata
- accession: 0001193125-23-237632
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523237632/0001193125-23-237632-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523237632/d511672d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-237632
- JSON: https://secwatch.observer/filing/0001193125-23-237632.json
- Plain text: https://secwatch.observer/filing/0001193125-23-237632.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.